ChitogenX Inc. is focused on the following four (4) strategies to create value for its investors: 1. Prioritize activities that will lead to faster commercial status, enabling the Company to leverage on its ability to provide potential licensees with a reliable source of cGMP sterile Chitosan-Based Polymer.

2. Leverage non-dilutive grants secured with Montreal Polytechnique’s partnership to drive proof of concept in multiple indications for the Company’s Chitosan-Based Biopolymer.

3. Leverage its IP portfolio and proof of concept data to attract partnership agreements.

4. Leverage safety data from the completed Rotator Cuff Tear Repair U.S. phase I/II clinical trial to establish and validate the regenerative medicine platform.